Overview
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
Associated Conditions
No associated conditions information available.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/08/22 | Not Applicable | Not yet recruiting | |||
2025/08/19 | Not Applicable | Not yet recruiting | |||
2025/08/15 | Not Applicable | Not yet recruiting | Federation Francophone de Cancerologie Digestive | ||
2025/06/29 | Not Applicable | Not yet recruiting | |||
2025/06/09 | Phase 2 | Recruiting | |||
2025/05/28 | Phase 2 | Not yet recruiting | |||
2025/03/04 | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | ||
2025/01/24 | Phase 2 | Recruiting | |||
2025/01/14 | Phase 2 | Recruiting | |||
2024/11/12 | Phase 2 | Recruiting | Dai, Guanghai |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Takeda Pharmaceuticals America, Inc. | 63020-225 | ORAL | 5 mg in 1 1 | 11/14/2023 | |
| Takeda Pharmaceuticals America, Inc. | 63020-210 | ORAL | 1 mg in 1 1 | 11/14/2023 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 6/20/2024 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| FRUZAQLA CAPSULE 5MG | SIN17113P | CAPSULE | 5mg | 10/17/2024 | |
| FRUZAQLA CAPSULE 1MG | SIN17114P | CAPSULE | 1mg | 10/17/2024 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| FRUZAQLA fruquintinib 5 mg hard capsule bottle | 422038 | Medicine | A | 10/1/2024 | |
| FRUZAQLA fruquintinib 1 mg hard capsule bottle | 422039 | Medicine | A | 10/1/2024 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| FRUZAQLA 5 MG CAPSULAS DURAS | 1241827002 | CÁPSULA DURA | Diagnóstico Hospitalario | Commercialized | |
| FRUZAQLA 1 MG CAPSULAS DURAS | 1241827001 | CÁPSULA DURA | Diagnóstico Hospitalario | Commercialized |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.